Product Center
2024-2025 Flu Season HRK-X Approved for Market Launch
- Categories:Company news
- Author:
- Origin:
- Time of issue:2024-06-12
- Views:
(Summary description)On June 12, 2024, China Wisdom Bio's quadrivalent influenza virus subunit vaccine HRK-X for the 2024-2025 influenza season received the Certificate of Approval for Biological Products issued by the National Medical Products Administration (NMPA). As China's only approved subunit influenza vaccine of its kind, it will be quickly distributed nationwide to safeguard the health of the Chinese people.
2024-2025 Flu Season HRK-X Approved for Market Launch
(Summary description)On June 12, 2024, China Wisdom Bio's quadrivalent influenza virus subunit vaccine HRK-X for the 2024-2025 influenza season received the Certificate of Approval for Biological Products issued by the National Medical Products Administration (NMPA). As China's only approved subunit influenza vaccine of its kind, it will be quickly distributed nationwide to safeguard the health of the Chinese people.
- Categories:Company news
- Author:
- Origin:
- Time of issue:2024-06-12 17:31
- Views:
On June 12, 2024, China Wisdom Bio's quadrivalent influenza virus subunit vaccine HRK-X for the 2024-2025 influenza season received the Certificate of Approval for Biological Products issued by the National Medical Products Administration (NMPA). As China's only approved subunit influenza vaccine of its kind, it will be quickly distributed nationwide to safeguard the health of the Chinese people.
As a third-generation influenza vaccine, the quadrivalent influenza virus subunit vaccine HRK-X utilizes a unique extraction process for influenza virus subunits (HA: hemagglutinin and NA: neuraminidase), which ensures both high purity of the vaccine strain's HA and NA content (over 85%) and vaccine safety, while delivering good immunogenicity. Many of the product's quality standards exceed those of the Chinese and EU Pharmacopoeias and have reached internationally advanced levels.
The approval of HRK-X will provide a better vaccination option for the 2024-2025 influenza season and support influenza prevention and control efforts.
According to statistics, China reported 12.52 million influenza cases in 2023, a 5.1-fold increase from 2022.
Influenza (commonly known as "flu") is an acute respiratory infectious disease caused by the influenza virus, posing a serious health risk to humans. Influenza viruses exhibit antigenic variability and spread rapidly, causing seasonal epidemics annually. Outbreaks frequently occur in crowded settings such as schools, childcare institutions, and nursing homes. The general population is susceptible to influenza virus, with high-risk groups (including pregnant women, infants, the elderly, and chronic disease patients) facing more severe consequences from infection.
According to China CDC's infectious disease surveillance data: in 2023, reported influenza cases surpassed 10 million, reaching 12.52 million cases - a 5.1-fold increase from 2022. The World Health Organization (WHO) Influenza Vaccine Position Paper (2022 Edition) and China's Influenza Vaccination Technical Guidelines (2023-2024) both recommend annual influenza vaccination as the most effective prevention method, which can significantly reduce the risk of influenza and serious complications among vaccine recipients.
Relevant information
-
The Launch Meeting of Phase I/II Clinical Trial for Recombinant Herpes Zoster Vaccine (CHO Cell) was successfully heldRecently, the Phase I/II clinical trial launch meeting for the recombinant herpes zoster vaccine (CHO cell), co-developed by Ab&B Bio-Tech CO., LTD. JS. and Yither Biotech (Shanghai) Co., Ltd., was successfully held in Henan, and the first-in-human (FIH) dosing was successfully completed. - Ab&B Bio and Yither Bio Have Both Obtained Qualification Certification! 12-30
- Kickoff Meeting for Clinical Research on Quadrivalent Influenza Virus Subunit Vaccine in Children with Nephrotic Syndrome Successfully Held 12-25
- IND Application for Influenza Virus Subunit Vaccine (Adjuvanted) Approved 10-30
- The Application for the Marketing of Trivalent Influenza Virus Subunit Vaccine has been Accepted! 10-08
Got a project? Contact us today !
At Ab&B Bio, our mission is to care for life and protect health by developing globally innovative vaccines.
Contact
E-mail:haixin.zhang@yitherbiotech.com
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City
Quick view
Follow us
